Navigation Links
Lexicon Completes Phase 2 Study Of LX1033 In IBS-d
Date:12/3/2013

tment arms and placebo.

"While LX1033 showed similar improvements in stool consistency as compared to the placebo patients who completed the study, there were positive effects on abdominal pain in the treated group that warrant further study," said Pablo Lapuerta, M.D., Lexicon's chief medical officer. "While this initial Phase 2a study was underway, we completed long-term toxicology studies which would allow us to conduct a Phase 2b study at doses informed by the current results and with a duration of 12 weeks, a treatment period that has historically been important to identify clinically meaningful changes as compared to placebo."

In this Phase 2 study of IBS-d, 373 patients were randomized to be treated for 28 days with either placebo or one of three different dose levels of LX1033 for 28 days, 1000 mg twice daily, 500 mg twice daily, and 500 mg three times daily. The primary endpoint was the change from baseline in stool consistency as evaluated by the Bristol Stool Form Scale. A key secondary endpoint was the change from baseline in abdominal pain, and other endpoints included the change in plasma 5-HIAA.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has multiple programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement
This press release contains "forward-lookin
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Provide First Quarter 2012 Financial Results
2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
3. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
4. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
5. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
6. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
8. Lexicon to Provide Second Quarter 2012 Financial Results
9. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
10. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
11. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 /PRNewswire-iReach/ -- ChemImage announced today ... improvements in the development of imaging technology ... normal and diseased tissue that minimizes the ... procedures, lowers surgical costs and potentially enhances ... The clinical and scientific teams ...
(Date:9/17/2014)... 17, 2014 Prostate Oncology Specialists announces ... to educate men about new imaging technology destined ... prostate. Annually, a million men undergo random needle ... MRI (MP-MRI) of the prostate gland is non-invasive ... need to be fully informed of their alternatives. ...
(Date:9/17/2014)... , Sept. 17, 2014  Rebiotix Inc. announced this morning ... lead product candidate, RBX2660 (microbiota suspension) will be presented in ... conference in Philadelphia from October 8-12. ... during the poster session on Thursday, October 9, 2014: ... Infection: 60-Day Interim Analysis of the PUNCH-CD Phase 2 ...
Breaking Medicine Technology:Patient Outcomes Improve When Molecular Chemical Imaging Technology Is Used to Aid Robotic Surgical Procedures, According to New White Paper 2Prostate Cancer Awareness Month - Stop Random Biopsies 2Prostate Cancer Awareness Month - Stop Random Biopsies 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 2PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 3PUNCH CD Study Drug Targeting Recurrent C. difficile Infection to be Presented at IDWeek 2014 4
... ... ... ... ...
... , ... ... ... ...
Cached Medicine Technology:American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 2American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 3American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 4American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 5American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 6American Stroke Association Late-Breaking Science Report: New Drug as Effective as Warfarin in Preventing Strokes in Atrial Fibrillation Patients With Prior Stroke or TIA 7Dialysis Corporation of America Announces Fiscal Year 2009 Earnings Release Date 2Dialysis Corporation of America Announces Fiscal Year 2009 Earnings Release Date 3Dialysis Corporation of America Announces Fiscal Year 2009 Earnings Release Date 4
(Date:9/17/2014)... WEDNESDAY, Sept. 17, 2014 (HealthDay News) -- A blood ... could provide doctors with a better assessment of the ... If used routinely, this blood test could ... working and actually begins promoting tumor growth, the researchers ... given to patients with advanced prostate cancer and often ...
(Date:9/17/2014)... at The Scripps Research Institute (TSRI) have devised ... powerfully effective against vancomycin-resistant strains of MRSA and ... appears to have not one but two distinct ... cannot evolve resistance quickly. , "This is the ... be in clinical use a generation or maybe ...
(Date:9/17/2014)... 2014 Prevention is the best treatment ... scores of infants, children and teenagers in 12 states, ... medical director of Legacy ER & Urgent Care (LER) ... reported cases of EV-D68 so far in North Texas, ... change,” he said. “Implementing prevention strategies now may help ...
(Date:9/17/2014)... (PRWEB) September 18, 2014 Many countries ... influenza, instead of immunizations. The total number of poultry ... difficult to control, will result in huge losses. Therefore, ... avian influenza vaccines. , Avian influenza vaccines have been ... poultry farms in China began to use H5N1 avian ...
(Date:9/17/2014)... 2014 The Food and Drug Administration ... 2014, to consider: , 1. The ... 2. The potential for adverse cardiovascular ... TRT litigation ongoing, an informally-organized litigation group subcommittee prepared ... testosterone replacement therapy. Among others, ZKB attorney Michelle L. ...
Breaking Medicine News(10 mins):Health News:DNA Blood Test Might Identify Status of Prostate Cancer 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 2Health News:Scripps Research Institute chemists modify antibiotic to vanquish resistant bacteria 3Health News:Legacy ER & Urgent Care Warns North Texans about Dangers of Enterovirus D68 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 3Health News:FDA Advisory Committee Holds Hearing on Testosterone Safety 2
... Dr. ... ... Marc Sedwitz, MD, as the new chief of staff of the 372-bed facility. Dr. Sedwitz will ... , ,During his two-year term, Dr. Sedwitz will serve as medical staff liaison to Scripps La ...
... , , SANTA ANA, Calif., Dec. 14 Grubb ... of directors has authorized a daily distribution to stockholders of record ... period commencing on Jan. 1, 2010 and ending on Feb. 28, ... in the calendar year and will be equal to an annualized ...
... to scans performed in 2007 , MONDAY, Dec. 14 ... to far more radiation than previously thought and in doses ... two new studies claim. , Based on the findings, reported ... Internal Medicine , the study authors, joined by Archives ...
... are underdiagnosed, poorly treated and highly stigmatized, according to ... M.D., Ph.D. So these Washington University physicians have written ... Psychiatry," Zorumski and Rubin, who have more than 50 ... families, say some of the problems related to psychiatric ...
... ... tipped off a promotion--Send a Net. Save a Life. See a Game. presented by HP--to ... the NBA Cares Season of Giving and runs through January 31, 2010. ... New York, NY (Vocus) December ...
... , , ... year-old mother from Phoenix who lost 120 pounds (half her size) in ... weight-loss program and foods, appeared this morning on the Joy Fit Club ... nutritionist and author Joy Bauer, airs twice a month and salutes those ...
Cached Medicine News:Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 2Health News:New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla 3Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 2Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 3Health News:Studies Quantify Cancer Risks From CT Scans 2Health News:Studies Quantify Cancer Risks From CT Scans 3Health News:Studies Quantify Cancer Risks From CT Scans 4Health News:Book demystifies psychiatry for the general public 2Health News:Book demystifies psychiatry for the general public 3Health News:NBA Cares and United Nations Foundation Partner to Launch Send A Net. Save A Life. See A Game. Presented By HP 2Health News:NBA Cares and United Nations Foundation Partner to Launch Send A Net. Save A Life. See A Game. Presented By HP 3Health News:NBA Cares and United Nations Foundation Partner to Launch Send A Net. Save A Life. See A Game. Presented By HP 4Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 2Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 3Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: